

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

ANNOUNCEMENT ON ADJUSTMENT OF SHARE PRICE CAP FOR REPURCHASE OF A SHARES

Reference is made to the announcement dated 16 August 2024 of Shanghai Haohai Biological Technology Co., Ltd.* (the **“Company”**) in relation to the plan on repurchase of A shares of the Company (the **“A Share(s)”**) through centralized bidding trading.

On 16 August 2024, the board of directors of the Company (the **“Board”**) approved the Second Plan on the Repurchase of A Shares through Centralized Bidding Trading (the **“Repurchase Plan”**). Pursuant to the Repurchase Plan, the Company will repurchase A Shares through centralized bidding trading within 12 months from the date of approval of the Repurchase Plan by the Board (the **“Repurchase Period”**). The total amount of funds for the repurchase of A Shares shall be not less than RMB100 million (inclusive) and not more than RMB200 million (inclusive), and the repurchase price shall not exceed RMB89.71 per A Share (inclusive). According to the Repurchase Plan, if the Company carried out any conversion of capital reserve into share capital, distribution of shares or cash dividends, rights issue, share sub-division or consolidation or other events such as ex-right and ex-dividend related matters during the Repurchase Period, the Company will make corresponding adjustments to the repurchase price cap pursuant to relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.

On 13 September 2024, the Company's 2024 Interim Profit Distribution Plan has been approved at the 2024 first extraordinary general meeting of the Company. Accordingly, the Company adjusted the repurchase price of A Shares from no more than RMB89.71 per A Share (inclusive) to no more than RMB89.31 per A Share (inclusive) in accordance with the Repurchase Plan.

On 10 June 2025, the Company's 2024 profit distribution plan has been approved at the 2024 annual general meeting. Accordingly, the Company will distribute a final dividend of RMB0.60 per Share (tax inclusive) to shareholders for the year ended 31 December 2024 (the **“Final Dividend Distribution”**). In view of the completion of the Final Dividend Distribution of A Shares on 30 June 2025 (being the ex-right and ex-dividend date of the A Shares), the Company has adjusted the repurchase price cap accordingly in accordance with the Repurchase Plan. After adjustment, the repurchase price of A Shares was adjusted from no more than RMB89.31 per A Share (inclusive) to no more than RMB88.72 per A Share (inclusive).

Save for the aforesaid adjustment, there is no change in other matters of the Repurchase Plan. The Company will continue to follow the Rules on Repurchase of Shares by Listed Companies (《上市公司股份回購規則》), the Self-Regulatory Guidelines No. 7 for Listed Companies on the Shanghai Stock Exchange – Share Repurchases (《上海證券交易所上市公司自律監管指引第 7 號 – 回購股份》) and other relevant regulations and the Repurchase Plan, select the opportunity to repurchase the shares according to the market situation during the Repurchase Period, and perform its information disclosure obligation in a timely manner according to the progress of the repurchase.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC, 30 June 2025

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie, Mr. Huang Ming and Mr. Wei Changzheng; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi and Mr. Yang Yushe.

* *For identification purpose only*